Datopotamab Deruxtecan vs Sacituzumab Govitecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT04656652 · Phase 3 · active, not recruiting
This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).
Next expected readout: January 2027 · NCT06417814 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)
Result source: NCT04656652
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT05089734 · Phase 3 · active, not recruiting
This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.
Next expected readout: January 2027 · NCT05609968 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)
Result source: NCT05089734
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Datopotamab Deruxtecan | Sacituzumab Govitecan |
|---|---|---|
| PFS, median | 4.4 vs 3.7vs DocetaxelNCT046566521 other result
| —Trial running · NCT05609968 |
| OS, median | 12.9 vs 11.8vs DocetaxelNCT04656652 | —Trial running · NCT05609968 |
| ORR | 35.8%bNCT04484142 | —Trial running · NCT05609968 |
| Duration of response, median | —Trial running · NCT04656652 | —Trial running · NCT05609968 |
PFS, median
- Datopotamab Deruxtecan
- 4.4 vs 3.7vs DocetaxelNCT04656652
1 other result
- 4.4 vs 3 NCT04656652
- Sacituzumab Govitecan
- —Trial running · NCT05609968
OS, median
- Datopotamab Deruxtecan
- 12.9 vs 11.8vs DocetaxelNCT04656652
- Sacituzumab Govitecan
- —Trial running · NCT05609968
ORR
- Datopotamab Deruxtecan
- 35.8%bNCT04484142
- Sacituzumab Govitecan
- —Trial running · NCT05609968
Duration of response, median
- Datopotamab Deruxtecan
- —Trial running · NCT04656652
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Datopotamab Deruxtecan: 4 of 4 rows · Sacituzumab Govitecan: 1 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan | Sacituzumab Govitecan |
|---|---|---|
| Dropout rate | 77.3%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result85.4%6.0 mg/kg Q3W NCT04484142 · Phase 2 | 4.8%10 mg/kgb NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result9.5%6.0 mg/kg Q3W NCT04484142 · Phase 2 | —10 mg/kgb NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 31%6.0 mg/kga NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result24.8%6.0 mg/kg Q3W NCT04484142 · Phase 2 | —10 mg/kgb NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 6.0 mg/kga stomatitis 49.8% nausea 37.7% alopecia 32% NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result | — |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT05104866 · Phase 3 · active, not recruiting
Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)
Result source: NCT05104866
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT03901339 · Phase 3 · completed
The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)
Result source: NCT03901339
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Datopotamab Deruxtecan | Sacituzumab Govitecan |
|---|---|---|
| PFS, median | 6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)NCT051048661 other result
| 5.5 vs 4vs Treatment of Physician's ChoiceNCT039013391 other result
|
| OS, median | 18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)NCT05104866 | 14.5 vs 11.2vs Treatment of Physician's ChoiceNCT03901339 |
| ORR | —Trial running · NCT05104866 | —Trial running · NCT05840211 |
| Clinical benefit rate | —Trial running · NCT05104866 | —Trial running · NCT05840211 |
PFS, median
- Datopotamab Deruxtecan
- 6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)NCT05104866
1 other result
- 6.9 vs 4.5 NCT05104866
- Sacituzumab Govitecan
- 5.5 vs 4vs Treatment of Physician's ChoiceNCT03901339
1 other result
- 4.3 vs 3.1 NCT03901339
OS, median
- Datopotamab Deruxtecan
- 18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)NCT05104866
- Sacituzumab Govitecan
- 14.5 vs 11.2vs Treatment of Physician's ChoiceNCT03901339
ORR
- Datopotamab Deruxtecan
- —Trial running · NCT05104866
- Sacituzumab Govitecan
- —Trial running · NCT05840211
Clinical benefit rate
- Datopotamab Deruxtecan
- —Trial running · NCT05104866
- Sacituzumab Govitecan
- —Trial running · NCT05840211
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Datopotamab Deruxtecan: 2 of 4 rows · Sacituzumab Govitecan: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan | Sacituzumab Govitecan |
|---|---|---|
| Dropout rate | n/a: no completion milestone NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | n/a: no completion milestone NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | — NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 17.2% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 27.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 56.7% stomatitis 52.2% alopecia 37.8% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | neutropenia 68.7% diarrhoea 60.8% nausea 58.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
Sacituzumab Govitecan
Breast Cancer
Shared mechanism: TROP2 · full Breast Cancer pipeline
Datopotamab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT05104866 · Phase 3 · active, not recruiting
Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)
Result source: NCT05104866
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT03901339 · Phase 3 · completed
The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)
Result source: NCT03901339
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Datopotamab Deruxtecan: 4 of 6 rows · Sacituzumab Govitecan: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Datopotamab Deruxtecan | Sacituzumab Govitecan |
|---|---|---|
| Overall Survival time to event · months | 18.6 vs 18.3 Investigator's Choice of Chemotherapy (ICC) monthsa,b,c NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 14.5 vs 11.2 Treatment of Physician's Choice monthsa,b,c NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 2 other source trials12.1 vs 6.7 Treatment of Physician's Choice (TPC) months NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 11.8 vs 6.9 Treatment of Physician's Choice (TPC) months NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 |
| PFS time to event · months | 6.9 vs 4.9 Investigator's Choice of Chemotherapy (ICC) monthsd,a,b,c NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose6.9 vs 4.5 Investigator's Choice of Chemotherapy (ICC) months NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 5.5 vs 4 Treatment of Physician's Choice monthsd,a,b,c NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose4.3 vs 3.1 Treatment of Physician's Choice months NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | n/a: no completion milestone NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | n/a: no completion milestonee NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more resultsn/a: no completion milestone NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 4.8%10 mg/kg NCT01631552 · Phase 1/2 |
| Discontinued due to AEs | — NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —e NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more results— NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 —10 mg/kg NCT01631552 · Phase 1/2 |
| Serious AEs | 17.2% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 27.6%e NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more results26.7% NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 —10 mg/kg NCT01631552 · Phase 1/2 |
| Most frequent reported AEs | nausea 56.7% stomatitis 52.2% alopecia 37.8% NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | e neutropenia 68.7% diarrhoea 60.8% nausea 58.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result |
Notes
- aPopulation context differs: baseline_threshold differs (lvef>=50 versus none recorded); prior_therapy differs (none recorded versus experienced).
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Datopotamab Deruxtecan
show 1 more result
Sacituzumab Govitecan
show 1 more result
show 1 more result
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · Sacituzumab Govitecan's landscape